Influence of the scan time point when assessing hypoxia in 18F-fluoromisonidazole PET: 2 vs. 4 h
- 45 Downloads
18F-fluoromisonidazole (18F-FMISO) is the most widely used positron emission tomography (PET) tracer for imaging tumor hypoxia. Previous reports suggested that the time from injection to the scan may affect the assessment of 18F-FMISO uptake. Herein, we directly compared the images at 2 h and 4 h after a single injection of 18F-FMISO.
Twenty-three patients with or suspected of having a brain tumor were scanned twice at 2 and 4 h following an intravenous injection of 18F-FMISO. We estimated the mean standardized uptake value (SUV) of the gray matter and white matter and the gray-to-white matter ratio in the background brain tissue from the two scans. We also performed a semi-quantitative analysis using the SUVmax and maximum tumor-to-normal ratio (TNR) for the tumor.
At 2 h, the SUVmean of gray matter was significantly higher than that of white matter (median 1.23, interquartile range (IQR) 1.10–1.32 vs. 1.04, IQR 0.95–1.16, p < 0.0001), whereas at 4 h, it significantly decreased to approach that of the white matter (1.10, IQR 1.00–1.23 vs. 1.02, IQR 0.93–1.13, p = NS). The gray-to-white matter ratio thus significantly declined from 1.17 (IQR 1.14–1.19) to 1.09 (IQR 1.07–1.10) (p < 0.0001). All 7 patients with glioblastoma showed significant increases in the SUVmax (2.20, IQR 1.67–3.32 at 2 h vs. 2.65, IQR 1.74–4.41 at 4 h, p = 0.016) and the TNR (1.75, IQR 1.40–2.38 at 2 h vs. 2.34, IQR 1.67–3.60 at 4 h, p = 0.016).
In the assessment of hypoxic tumors, 18F-FMISO PET for hypoxia imaging should be obtained at 4 h rather than 2 h after the injection.
KeywordsFluoromisonidazole Positron emission tomography Glioblastoma Hypoxia Scan timing This article is part of the Topical Collection on Oncology – Brain
We thank the staff members of the Department of Nuclear Medicine, the Central Institute of Isotope Science, the Department of Cancer Pathology, Hokkaido University, and the Department of Radiology, Hokkaido University Hospital, for their support of this work.
This research was supported in part by a Grant-in-Aid for General Scientific Research from the Japan Society for the Promotion of Science (Ko.Ke., 19K17127).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. A portion of our results were presented at the SNMMI 2018 Conference (J Nucl Med May 1, 2015, vol. 56 no. supplement 3373).
The requirement for written informed consent was waived due to the retrospective nature of this study.
- 8.Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704. https://doi.org/10.1007/s00259-002-1096-7.CrossRefPubMedGoogle Scholar
- 12.Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410–8.Google Scholar
- 13.Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30. https://doi.org/10.1158/1078-0432.ccr-07-4995.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC Jr, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69:4502–9. https://doi.org/10.1158/0008-5472.can-08-3884.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y, et al. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2011;38:441–50. https://doi.org/10.1007/s00259-010-1645-4.CrossRefPubMedGoogle Scholar
- 18.Yamaguchi S, Hirata K, Toyonaga T, Kobayashi K, Ishi Y, Motegi H, et al. Change in 18F-fluoromisonidazole PET is an early predictor of the prognosis in the patients with recurrent high-grade glioma receiving bevacizumab treatment. PLoS One. 2016;11:e0167917. https://doi.org/10.1371/journal.pone.0167917.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. (1)(8)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39:760–70. https://doi.org/10.1007/s00259-011-2037-0.CrossRefGoogle Scholar
- 23.Kanoto M, Kirii K, Hiraka T, Toyoguchi Y, Sugai Y, Matsuda K, et al. Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography. Acta Radiol. 2018;59:229–35. https://doi.org/10.1177/0284185117711474.CrossRefGoogle Scholar
- 31.Masaki Y, Shimizu Y, Yoshioka T, Tanaka Y, Nishijima K, Zhao S, et al. The accumulation mechanism of the hypoxia imaging probe “FMISO” by imaging mass spectrometry: possible involvement of low-molecular metabolites. Sci Rep. 2015;5:16802. https://doi.org/10.1038/srep16802.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113:1032–42. https://doi.org/10.1002/cncr.23678.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans JM, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383–92. https://doi.org/10.1007/s00259-017-3677-5.CrossRefGoogle Scholar
- 38.Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, et al. (18)F-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:261–70. https://doi.org/10.1016/j.oooo.2017.05.506.CrossRefPubMedGoogle Scholar
- 44.Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91:351–9. https://doi.org/10.1016/j.ijrobp.2014.09.045.CrossRefPubMedGoogle Scholar